Long-term overall and relapse-free survival in a patient with metastatic non-small cell lung cancer treated with immunotherapy. A case report ; Длительная общая и безрецидивная выживаемость у пациента с метастатическим НМРЛ на фоне иммунотерапевтического лечения. Клинический случай

Authors: G. V. Afonin, V. Yu. Skoropad, A. E. Glukhareva, E. I. Kupriyanova, T. A. Agababyan, S. A. Ivanov, A. D. Kaprin, Г. В. Афонин, В. Ю. Скоропад, А. Е. Глухарева, Е. И. Куприянова, Т. А. Агабабян, С. А. Иванов, А. Д. Каприн

Source: Siberian journal of oncology; Том 23, № 6 (2024); 176-184 ; Сибирский онкологический журнал; Том 23, № 6 (2024); 176-184 ; 2312-3168 ; 1814-4861

Subject Terms: статус PD-L1, drug therapy, immune response checkpoint inhibitors, PD-L1 status, лекарственная терапия, ингибиторы контрольных точек иммунного ответа

File Description: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/3349/1294; Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229–63. doi:10.3322/caac.21834.; Состояние онкологической помощи населению России в 2022 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2023. 252 с.; Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzáles-Larriba J.L., Grodzki T., Pereira J.R., Le Groumellec A., Lorusso V., Clary C., Torres A.J., Dahabreh J., Souquet P.J., Astudillo J., Fournel P., Artal-Cortes A., Jassem J., Koubkova L., His P., Riggi M., Hurteloup P. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial. Lancet Oncol. 2006; 7(9): 719–27. doi:10.1016/S1470-2045(06)70804-X. Erratum in: Lancet Oncol. 2006; 7(10): 797.; McMurry T.L., Stukenborg G.J., Kessler L.G., Colditz G.A., Wong M.L., Francescatti A.B., Jones D.R., Schumacher J.R., Greenberg C.C., Chang G.J., Winchester D.P., McKellar D.P., Kozower B.D. More Frequent Surveillance Following Lung Cancer Resection Is Not Associated With Improved Survival: A Nationally Representative Cohort Study. Ann Surg. 2018; 268(4): 632–39. doi:10.1097/SLA.0000000000002955.; Boyd J.A., Hubbs J.L., Kim D.W., Hollis D., Marks L.B., Kelsey C.R. Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure. J Thorac Oncol. 2010; 5(2): 211–14. doi:10.1097/JTO.0b013e3181c20080.; Choi P.J., Jeong S.S., Yoon S.S. Prediction and prognostic factors of post-recurrence survival in recurred patients with early-stage NSCLC who underwent complete resection. J Thorac Dis. 2016; 8(1): 152–60. doi:10.3978/j.issn.2072-1439.2016.01.10.; Sekihara K., Hishida T., Yoshida J., Oki T., Omori T., Katsumata S., Ueda T., Miyoshi T., Goto M., Nakasone S., Ichikawa T., Matsuzawa R., Aokage K., Goto K., Tsuboi M. Long-term survival outcome after postoperative recurrence of non-small-cell lung cancer: who is ‘cured’ from postoperative recurrence? Eur J Cardiothorac Surg. 2017; 52(3): 522–28. doi:10.1093/ejcts/ezx127.; Tan W.L., Jain A., Takano A., Newell E.W., Iyer N.G., Lim W.T., Tan E.H., Zhai W., Hillmer A.M., Tam W.L., Tan D.S.W. Novel therapeutic targets on the horizon for lung cancer. Lancet Oncol. 2016; 17(8): 347–62. doi:10.1016/S1470-2045(16)30123-1.; Bai R., Lv Z., Xu D., Cui J. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res. 2020; 8: 34. doi:10.1186/s40364-020-00209-0.; Antonia S., Goldberg S.B., Balmanoukian A., Chaft J.E., Sanborn R.E., Gupta A., Narwal R., Steele K., Gu Y., Karakunnel J.J., Rizvi N.A. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016; 17(3): 299–308. doi:10.1016/S1470-2045(15)00544-6.; Rizvi N.A., Cho B.C., Reinmuth N., Lee K.H., Luft A., Ahn M.J., van den Heuvel M.M., Cobo M., Vicente D., Smolin A., Moiseyenko V., Antonia S.J., Le Moulec S., Robinet G., Natale R., Schneider J., Shepherd F.A., Geater S.L., Garon E.B., Kim E.S., Goldberg S.B., Nakagawa K., Raja R., Higgs B.W., Boothman A.M., Zhao L., Scheuring U., Stockman P.K., Chand V.K., Peters S.; MYSTIC Investigators. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(5): 661–74. doi:10.1001/jamaoncol.2020.0237. Erratum in: JAMA Oncol. 2020; 6(11): 1815.; Si H., Kuziora M., Quinn K.J., Helman E., Ye J., Liu F., Scheuring U., Peters S., Rizvi N.A., Brohawn P.Z., Ranade K., Higgs B.W., Banks K.C., Chand V.K., Raja R. A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. Clin Cancer Res. 2021; 27(6): 1631–40. doi:10.1158/1078-0432.CCR-20-3771.; Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC) [Internet]. Clinical Trials.gov. URL: https://clinicaltrials.gov/study/NCT02453282 [cited 10.09.2024].; Моисеенко Ф.В., Волков Н.М., Абдулоева Н.Х., Левченко Н.В., Чубенко В.А., Жабина А.С., Чернобривцева В.В., Шугинова Т.Н., Шелехова К.В., Хенштейн В.А., Степанова М.Л., Крамчанинов М.М., Белухин С.А., Хабичева А.М., Артемьева Е.В., Носова М.В., Тулейко В.М., Моисеенко В.М. Результаты применения иммунотерапевтических препаратов при немелкоклеточном раке легкого в реальной клинической практике. Злокачественные опухоли. 2020; 10(1): 5–20. doi:10.18027/2224-5057-2020-10-1-5-20.; https://www.siboncoj.ru/jour/article/view/3349

Availability: https://www.siboncoj.ru/jour/article/view/3349
https://doi.org/10.21294/1814-4861-2024-23-6-176-184

Nitric oxide in oncology: a two-faced Janus ; Оксид азота в онкологии: двуликий Янус

Authors: A. D. Kaprin, P. V. Shegai, O. A. Aleksandrov, O. V. Pikin, A. B. Ryabov, A. I. Garifullin, А. Д. Каприн, П. В. Шегай, О. А. Александров, О. В. Пикин, А. Б. Рябов, А. И. Гарифуллин

Source: PULMONOLOGIYA; Том 34, № 3 (2024); 401-408 ; Пульмонология; Том 34, № 3 (2024); 401-408 ; 2541-9617 ; 0869-0189

Subject Terms: канцерогенез, cancer, nitric oxide synthase, drug therapy, carcinogenesis, рак, синтазы оксида азота, лекарственная терапия

File Description: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/4562/3663; Ignarro L.J. Biosynthesis and metabolism of endothelium-derived nitric oxide. Ann. Rev. Pharmacol. Toxicol. 1990; 30: 535–560. DOI:10.1146/annurev.pa.30.040190.002535.; Knowles R.G., Moncada S. Nitric oxide synthases in mammals. Biochem. J. 1994; 298 (2): 249–258. DOI:10.1042/bj2980249.; Alderton W.K., Cooper C.E., Knowles R.G. Nitric oxide synthases: structure, function and inhibition. Biochem. J. 2001; 357 (Pt 3): 593–615. DOI:10.1042/bj3570593.; Korde Choudhari S., Chaudhary M., Bagde S. et al. Nitric oxide and cancer: a review. World J. Surg. Oncol. 2013; 11: 118. DOI:10.1186/1477-7819-11-118.; Lundberg J.O., Weitzberg E. Nitric oxide signaling in health and disease. Cell. 2022; 185 (16): 2853–2878. DOI:10.1016/j.cell.2022.06.010.; Yu B., Ichinose F., Bloch D.B., Zapol W.M. Inhaled nitric oxide. Br. J. Pharmacol. 2019; 176 (2): 246–255. DOI:10.1111/bph.14512.; Calabrese E.J., Baldwin L.A. Defining hormesis. Hum. Exp. Toxicol. 2002; 21 (2): 91–97. DOI:10.1191/0960327102ht217oa.; Ridnour L.A., Isenberg J.S., Espey M.G. et al. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc. Natl. Acad. Sci. 2005; 102 (37): 13147–13152. DOI:10.1073/pnas.0502979102.; Kashfi K. The dichotomous role of H2S in cancer cell biology? Déjà vu all over again. Biochem. Pharmacol. 2018; 149: 205–223. DOI:10.1016/j.bcp.2018.01.042.; Sessa W.C. eNOS at a glance. J. Cell Sci. 2004; 117 (Pt 12): 2427–2429. DOI:10.1242/jcs.01165.; Kleinert H., Schwarz P.M., Förstermann U. Regulation of the expression of inducible nitric oxide synthase. Biol. Chem. 2003; 384 (10-11): 1343–1364. DOI:10.1515/BC.2003.152.; Goligorsky M.S., Brodsky S.V., Noiri E. NO bioavailability, endothelial dysfunction, and acute renal failure: new insights into pathophysiology. Semin. Nephrol. 2004; 24 (4): 316–323. DOI:10.1016/j.semnephrol.2004.04.003.; Vannini F., Kashfi K., Nath N. The dual role of iNOS in cancer. Redox Biol. 2015; 6: 334–343. DOI:10.1016/j.redox.2015.08.009.; McGinity C.L., Palmieri E.M., Somasundaram V. et al. Nitric oxide modulates metabolic processes in the tumor immune microenvironment. Int. J. Mol. Sci. 2021; 22 (13): 7068. DOI:10.3390/ijms22137068.; Fukumura D., Kashiwagi S., Jain R.K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer. 2006; 6 (7): 521–534. DOI:10.1038/nrc1910.; Hirst D., Robson T. Targeting nitric oxide for cancer therapy. J. Pharm. Pharmacol. 2010; 59 (1): 3–13. DOI:10.1211/jpp.59.1.0002.; Nguyen T., Brunson D., Crespi C.L. et al. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc. Natl. Acad. Sci. USA. 1992; 89 (7): 3030–3034. DOI:10.1073/pnas.89.7.3030.; Yang Y.C., Chou H.Y.E., Shen T.L. et al. Topoisomerase II-mediated DNA cleavage and mutagenesis activated by nitric oxide underlie the inflammation-associated tumorigenesis. Antioxid. Redox Signal. 2013; 18 (10): 1129–1140. DOI:10.1089/ars.2012.4620.; Morbidelli L., Donnini S., Ziche M. Role of nitric oxide in the modulation of angiogenesis. Curr. Pharm. Des. 2003; 9 (7): 521–530. DOI:10.2174/1381612033391405.; Zhou J., Schmid T., Brüne B. HIF-1alpha and p53 as targets of NO in affecting cell proliferation, death and adaptation. Curr. Mol. Med. 2004; 4 (7): 741–751. DOI:10.2174/1566524043359926.; Thomas D.D., Espey M.G., Ridnour L.A. et al. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide Hypoxic inducible factor 1α, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc. Natl. Acad. Sci. USA. 2004; 101 (24): 8894–8899. DOI:10.1073/pnas.0400453101.; Ha K.S., Kim K.M., Kwon Y.G. et al. Nitric oxide prevents 6‐hydroxydopamine‐induced apoptosis in PC12 cells through cGMP‐dependent PI3 kinase/Akt activation. FASEB J. 2003; 17 (9): 1036–1047. DOI:10.1096/fj.02-0738com.; Blaise G., Gauvin D., Gangal M., Authier S. Nitric oxide, cell signaling and cell death. Toxicology. 2005; 208 (2): 177–192. DOI:10.1016/j.tox.2004.11.032.; Maiuthed A., Bhummaphan N., Luanpitpong S. et al. Nitric oxide promotes cancer cell dedifferentiation by disrupting an Oct4:caveolin-1 complex: a new regulatory mechanism for cancer stem cell formation. J. Biol. Chem. 2018; 293 (35): 13534–13552. DOI:10.1074/jbc.RA117.000287.; Bonavida B., Baritaki S. Inhibition of epithelial-to-mesenchymal transition (EMT) in cancer by nitric oxide: pivotal roles of nitrosylation of NF-κB, YY1 and snail. For. Immunopathol. Dis. Ther. 2012; 3 (2): 125–133. DOI:10.1615/ForumImmunDisTher.2012006065.; Hickok J.R., Sahni S., Mikhed Y. et al. Nitric oxide suppresses tumor cell migration through N-Myc downstream-regulated Gene-1 (NDRG1) expression. J. Biol. Chem. 2011; 286 (48): 41413–41424. DOI:10.1074/jbc.M111.287052.; Vyas-Read S., Shaul P.W., Yuhanna I.S., Willis B.C. Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007; 293 (1): L212–221. DOI:10.1152/ajplung.00475.2006.; Wink D.A., Hines H.B., Cheng R.Y.S. et al. Nitric oxide and redox mechanisms in the immune response. J. Leukoc. Biol. 2011; 89 (6): 873–891. DOI:10.1189/jlb.1010550.; Huang Z., Fu J., Zhang Y. Nitric oxide donor-based cancer therapy: advances and prospects. J. Med. Chem. 2017; 60 (18): 7617–7635. DOI:10.1021/acs.jmedchem.6b01672.; Sorbo L.D., Michaelsen V.S., Ali A. et al. High doses of Inhaled nitric oxide as an innovative antimicrobial strategy for lung infections. Biomedicines. 2022; 10 (7): 1525. DOI:10.3390/biomedicines10071525.; Liu P.F., Zhao D.H., Qi Y. et al. The clinical value of exhaled nitric oxide in patients with lung cancer. Clin. Respir. J. 2018; 12 (1): 23–30. DOI:10.1111/crj.12471.; Li C.Y., Anuraga G., Chang C.P. et al. Repurposing nitric oxide donating drugs in cancer therapy through immune modulation. J. Exp. Clin. Cancer Res. 2023; 42 (1): 22. DOI:10.1186/s13046-022-02590-0.; Stevens E.V., Carpenter A.W., Shin J.H. et al. Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth. Mol. Pharm. 2010; 7 (3): 775–785. DOI:10.1021/mp9002865.; Munaweera I., Shi Y., Koneru B. et al. Nitric oxide- and cisplatin-releasing silica nanoparticles for use against non-small cell lung cancer. J. Inorg. Biochem. 2015; 153: 23–31. DOI:10.1016/j.jinorgbio.2015.09.002.; Thakkar S., Sharma D., Kalia K., Tekade R.K. Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: a review. Acta Biomater. 2020; 101: 43–68. DOI:10.1016/j.actbio.2019.09.009.; Dong X., Liu H.J., Feng H.Y. et al. Enhanced drug delivery by nanoscale integration of a nitric oxide donor to induce tumor collagen depletion. Nano Lett. 2019; 19 (2): 997–1008. DOI:10.1021/acs.nanolett.8b04236.; Sung Y.C., Jin P.R., Chu L.A. et al. Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies. Nat. Nanotechnol. 2019; 14 (12): 1160–1169. DOI:10.1038/s41565-019-0570-3.; Jiang W., Dong W., Li M. et al. Nitric oxide induces immunogenic cell death and potentiates cancer immunotherapy. ACS Nano. 2022; 16 (3): 3881–3894. DOI:10.1021/acsnano.1c09048.; Levy E.S., Morales D.P., Garcia J.V. et al. Near-IR mediated intracellular uncaging of NO from cell targeted hollow gold nanoparticles. Chem. Commun. (Camb). 2015; 51 (100): 17692–17695. DOI:10.1039/C5CC07989F.; Wang L., Chang Y., Feng Y. et al. Nitric oxide stimulated programmable drug release of nanosystem for multidrug resistance cancer therapy. Nano Lett. 2019; 19 (10): 6800–6811. DOI:10.1021/acs.nanolett.9b01869.; Ishima Y., Fang J., Kragh-Hansen U. et al. Tuning of poly-S-nitrosated human serum albumin as superior antitumor nanomedicine. J. Pharm. Sci. 2014; 103 (7): 2184–2188. DOI:10.1002/jps.24020.; Heinecke J.L., Ridnour L.A., Cheng R.Y.S. et al. Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression. Proc. Natl. Acad. Sci. USA. 2014; 111 (17): 6323–6328. DOI:10.1073/pnas.1401799111.; Girotti A.W., Bazak J., Korytowski W. Pro-tumor activity of endogenous nitric oxide in anti-tumor photodynamic therapy: recently recognized bystander effects. Int. J. Mol. Sci. 2023; 24 (14): 11559. DOI:10.3390/ijms241411559.; Cheng R.Y.S., Ridnour L.A., Wink A.L. et al. Interferon-gamma is quintessential for NOS2 and COX2 expression in ER- breast tumors that lead to poor outcome. Cell Death Dis. 2023; 14 (5): 319. DOI:10.1038/s41419-023-05834-9.; Basudhar D., Glynn S.A., Greer M. et al. Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer. Proc. Natl. Acad. Sci. USA. 2017; 114 (49): 13030–13035. DOI:10.1073/pnas.1709119114.; Dávila-González D., Choi D.S., Rosato R.R. et al. Pharmacological inhibition of NOS activates ASK1/JNK pathway augmenting docetaxel-mediated apoptosis in triple-negative breast cancer. Clin. Cancer Res. 2018; 24 (5): 1152–1162. DOI:10.1158/1078-0432.CCR-17-1437.; Pershing N.L.K., Yang C.F.J., Xu M., Counter C.M. Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer. Oncotarget. 2106; 7 (27): 42385–42392. DOI:10.18632/oncotarget.9874.; https://journal.pulmonology.ru/pulm/article/view/4562

Availability: https://journal.pulmonology.ru/pulm/article/view/4562
https://doi.org/10.18093/0869-0189-2024-34-3-401-408

Efficacy of antiparkinsonian therapy in tremor correction according to tremorography ; Эффективность противопаркинсонической терапии в коррекции тремора по данным треморографии

Authors: V. A. Bogacheva, D. V. Zakharov, V. A. Mikhailov, В. А. Богачева, Д. В. Захаров, В. А. Михайлов

Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 2 (2024); 34-40 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 2 (2024); 34-40 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-2

Subject Terms: леводопа, tremor, drug therapy, levodopa, тремор, лекарственная терапия

File Description: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2222/1647; Литвиненко ИВ, Одинак ММ. Рациональный подход к медикаментозной терапии – основа обеспечения качества жизни при болезни Паркинсона. Военно-медицинский журнал. 2004;325(4):47-53.; Гусев ЕИ, Коновалов АН, Скворцова ВИ, Гехт АБ, редакторы. Неврология: Национальное руководство. Москва: ГЭОТАР-Медиа; 2009. 1035 с.; Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020 Feb 11;323(6):548-60. doi:10.1001/jama.2019.22360; Madelein van der Stouwe AM, Nieuwhof F, Helmich RC. Tremor pathophysiology: lessons from neuroimaging. Curr Opin Neurol. 2020 Aug;33(4):474-81. doi:10.1097/WCO.0000000000000829; Timmer J, Lauk M, Vach W, et al. A test for a difference between spectral peak frequencies. Comp Stat Data Anal. 1999;30:45-55.; Raethjen J, Govindan RB, Muthuraman M, et al. Cortical correlates of the basic and first harmonic frequency of Parkinsonian tremor. Clin Neurophysiol. 2009 Oct;120(10):1866-72. doi:10.1016/j.clinph.2009.06.028. Epub 2009 Sep 12.; Pollok B, Makhloufi H, Butz M, et al. Levodopa affects functional brain networks in Parkinsonian resting tremor. Mov Disord. 2009 Jan 15;24(1):91-8. doi:10.1002/mds.22318; Dirkx MF, Bologna M. The pathophysiology of Parkinson's disease tremor. J Neurol Sci. 2022 Apr 15;435:120196. doi:10.1016/j.jns.2022.120196. Epub 2022 Feb 19.; Голубев ВЛ. Диагностика и терапия дрожательной формы болезни Паркинсона. В кн.: Иллариошкин СН, Яхно НН, редакторы. Болезнь Паркинсона и расстройства движений. Москва: Диалог; 2008. С. 85-8.; Yaw TK, Fox SH, Lang AE. Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. Mov Disord Clin Pract. 2015 Dec 30;3(2):116-24. doi:10.1002/mdc3.12266; Нодель МР. Современные диагностические критерии болезни Паркинсона. Российский журнал гериатрической медицины. 2021;(1):92-6. doi:10.37586/2686-8636-1-2021-92-96; Протокол ведения больных. Болезнь Паркинсона (G20) [утвержден Минздравсоцразвития РФ 14.01.2005]. Проблемы стандартизации в здравоохранении. 2005;(3):74-166.; Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol. 2013 Jan;20(1):16-34. doi:10.1111/ene.12022. Erratum in: Eur J Neurol. 2013 Feb;20(2):406.; Федорова НВ, Шток ВН. Стратегия и тактика лечения болезни Паркинсона. Консилиум. 2001;(5):237-42.; Преображенская ИС, Яхно НН. Лечение болезни Паркинсона. Consilium Medicum. 2002;4(2):85–91.; Карабань ИН и др. Болезнь Паркинсона (G20): Клинические рекомендации. Новости медицины и фармации: Психиатрия и неврология. 2007;215. Доступно по ссылке: http://www.mif-ua.com/archive/article/1396 (дата обращения 19.02.2014).; Левин ОС. Стандарты лечения болезни Паркинсона. Лечащий врач. 2007;8/9. Доступно по ссылке: http://www.lvrach.ru/2007/08/4716383/ (дата обращения 20.06.2015).; Левин ОС, Датиева ВК. Тремор при болезни Паркинсона: особенности феноменологии и лечения. Современная терапия в психиатрии и неврологии. 2014;(3):14-9.; Голубев ВЛ. Алгоритм лечения ранних стадий болезни Паркинсона. Атмосфера: Нервные болезни: Неврологический алгоритм. 2005;(4):9-12.; Голубев ВЛ. Лечение болезни Паркинсона: решенные и нерешенные вопросы. В кн.: Избранные лекции по неврологии. Москва: Эйдос Медиа; 2006. С. 395-420.; Ghosh TK. Early Parkinson’s Disease Tremor Characteristics: Identification & Treatment. J Psychiatry Neurochem Res. 2023. Epub 04 Sep 2023.; Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):795-808. doi:10.1136/jnnp-2019-322338. Epub 2020 Jun 23.; Beckers M, Bloem BR, Verbeek MM. Mechanisms of peripheral levodopa resistance in Parkinson's disease. NPJ Parkinsons Dis. 2022 May 11;8(1):56. doi:10.1038/s41531-022-00321-y; Zach H, Dirkx MF, Roth D, et al. Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease. Neurology. 2020 Sep 15;95(11):e1461-e1470. doi:10.1212/WNL.0000000000010316. Epub 2020 Jul 10.; Смоленцева ИГ. Немоторные флуктуации при болезни Паркинсона. В кн.: Иллариошкин СН, Яхно НН, редакторы. Болезнь Паркинсона и расстройства движений. Москва: Диалог; 2008. С. 108-11.; Lenka A, Jankovic J. Tremor Syndromes: An Updated Review. Front Neurol. 2021 Jul 26;12:684835. doi:10.3389/fneur.2021.684835; De Bie RMA, Clarke CE, Espay AJ, et al. Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. Lancet Neurol. 2020 May;19(5):452-61. doi:10.1016/S1474-4422(20)30036-3. Epub 2020 Mar 12.; Рarkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Clin Neuropharmacol. 2000 Jan-Feb;23(1):34-44. doi:10.1097/00002826-200001000-00007; Pringsheim T, Day GS, Smith DB, et al; Guideline Subcommittee of the AAN. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology. 2021 Nov 16;97(20):942-57. doi:10.1212/WNL.0000000000012868; Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):713-20. doi:10.1136/jnnp.72.6.713; Elble RJ. Tremor and dopamine agonists. Neurology. 2002 Feb 26;58(4 Suppl 1):S57-62. doi:10.1212/wnl.58.suppl_1.s57; Карпова ЕА, Иванова-Смоленская ИА, Иллариошкин СН и др. Динамика основных симптомов болезни Паркинсона на фоне терапии пронораном. Неврологический журнал. 2003;8(2):49-52.; Левин ОС. Агонисты дофаминовых рецепторов в лечении болезни Паркинсона. Лечение нервных болезней. 2003;4.1(9):14-7.; Шавловская ОА. Качество жизни пациентов с болезнью Паркинсона на фоне терапии агонистами дофаминовых рецепторов. Ремедиум: Журнал о российском рынке лекарств и медицинской техники. 2014;(4):25-8.; Амирджанова ВН, Горячев ДВ, Коршунов НИ и др. Популяционные показатели качества жизни по опроснику SF-36: результаты многоцентрового исследования качества жизни «МИРАЖ». Научно-практическая ревматология. 2008;46(1):36-48. doi:10.14412/1995-4484-2008-852

Availability: https://nnp.ima-press.net/nnp/article/view/2222
https://doi.org/10.14412/2074-2711-2024-2-34-40

Опухоли головы и шеи

Authors: Л. В. Болотина, Л. Ю. Владимирова, Н. В. Деньгина, С. И. Кутукова, А. В. Новик, И. С. Романов

Source: Malignant tumours; Том 14, № 3s2-1 (2024); 160-182 ; Злокачественные опухоли; Том 14, № 3s2-1 (2024); 160-182 ; 2587-6813 ; 2224-5057

Subject Terms: лучевая терапия, плоскоклеточный рак, рак носоглотки, рак щитовидной железы, злокачественные новообразования слюнных желез, лекарственная терапия

File Description: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1365/970; https://www.malignanttumors.org/jour/article/view/1365

Availability: https://www.malignanttumors.org/jour/article/view/1365
https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-09

Рак желудка

Authors: Н. С. Бесова, Л. В. Болотина, С. В. Гамаюнов, А. Е. Калинин, Н. А. Козлов, О. А. Малихова, С. Н. Неред, С. С. Пирогов, С. А. Проценко, И. С. Стилиди, Г. М. Телетаева, М. Д. Тер-Ованесов, А. А. Трякин, В. М. Хомяков, М. В. Черных

Source: Malignant tumours; Том 14, № 3s2-1 (2024); 241-262 ; Злокачественные опухоли; Том 14, № 3s2-1 (2024); 241-262 ; 2587-6813 ; 2224-5057

Subject Terms: HER2, аденокарцинома желудка, аденокарцинома пищеводножелудочного перехода, лекарственная терапия, химиотерапия, трастузумаб, рамуцирумаб, ЭГДС, FISH

File Description: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1369/974; https://www.malignanttumors.org/jour/article/view/1369

Availability: https://www.malignanttumors.org/jour/article/view/1369
https://doi.org/10.18027/2224-5057-2024-14-3s2-1.1-13

Clinical and Economic Effectiveness of the Drug Sakubitril/ Valsartan in Treatment of Patients with Chronic Heart Failure with the Reduced Ejection Fraction in Conditions of Healthcare System of the Republic of Belarus

Source: Кардиология в Беларуси. :439-448

Subject Terms: 03 medical and health sciences, лекарственная терапия, 0302 clinical medicine, сакубирил/валсартан, sacubitril/valsartan, затратная эффективность, cost-effectiveness, хроническая сердечная недостаточность, 3. Good health, chronic heart failure, drug therapy

Diagnosis and Management of Peripheral Artery Diseases

Source: Кардиология в Беларуси. :390-408

Subject Terms: 03 medical and health sciences, лекарственная терапия, claudication, 0302 clinical medicine, заболевания периферических артерий, peripheral artery diseases, medical management, перемежающая хромота, реваскуляризация, revascularization, 3. Good health

Systemic therapy for metastatic pancreatic cancer ; Лекарственное лечение метастатического рака поджелудочной железы

Authors: Y. E. Chikhareva, M. Yu. Fedyanin, I. S. Bazin, I. A. Pokataev, A. A. Tryakin, Я. Е. Чихарева, М. Ю. Федянин, И. С. Базин, И. А. Покатаев, А. А. Трякин

Source: Malignant tumours; Том 13, № 4 (2023); 60-68 ; Злокачественные опухоли; Том 13, № 4 (2023); 60-68 ; 2587-6813 ; 2224-5057

Subject Terms: лекарственная терапия, systemic therapy

File Description: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1157/804; https://www.malignanttumors.org/jour/article/view/1157/908; Pancreatic Cancer — Cancer Stat Facts [Electronic resource]. URL: https://seer.cancer.gov/statfacts/html/pancreas.html (accessed: 21.01.2023).; Burris H.A. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. // Journal of Clinical Oncology. 1997. Vol. 15, №6.; Heinemann V. et al. Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer // Journal of Clinical Oncology. 2006. Vol. 24, № 24.; Rocha Lima C.M. et al. Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate // Journal of Clinical Oncology. 2004. Vol. 22, № 18.; Moore M.J. et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group // Journal of Clinical Oncology. 2007. Vol. 25, № 15.; Kordes S. et al. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer // Cancer Chemother Pharmacol. 2015. Vol. 75, №6.; Conroy T. et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer // New England Journal of Medicine. 2011. Vol. 364, № 19.; von Hoff D.D. et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine // New England Journal of Medicine. 2013. Vol. 369, № 18.; Wang-Gillam A. et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial // The Lancet. 2016. Vol. 387, № 10018.; Sohal D.P. S. et al. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial // JAMA Oncol. American Medical Association, 2021. Vol. 7, №3. P. 421–427.; Servetto A. et al. Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study // Cancers (Basel). 2021. Vol. 13, № 19. P. 4939.; Pusceddu S. et al. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis // Cancers (Basel). 2019. Vol. 11, №4.; Chiorean E.G. et al. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review // Therapeutic Advances in Medical Oncology. SAGE Publications Inc., 2019. Vol. 11.; Покатаев И.А. Консервативное лечение пациентов с местнораспространенным и метастатическим раком поджелудочной железы: автореф. дис. док. мед. наук 14.01.12 - 2020. – 25-27 с.; Wainberg Z.A. et al. A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluoro-uracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-nä ıve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). 2023.; Wang Y., Camateros P., Cheung W.Y. A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers // J Gastrointest Cancer. Humana Press Inc., 2019. Vol. 50, №1. P. 62–68.; Papneja N. et al. Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study // Pancreas. Lippincott Williams and Wilkins, 2019. Vol. 48, №7. P. 920–926.; Kordes M. et al. Survival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort // Cancers (Basel). 2019. Vol. 11, №9.; Cartwright T.H. et al. Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting // Drugs Real World Outcomes. Springer International Publishing, 2018. Vol. 5, №3. P. 149–159.; de Dosso S. et al. Treatment landscape of metastatic pancreatic cancer // Cancer Treat Rev. 2021. Vol. 96.; Tsang E.S. et al. Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer // Am J Clin Oncol. 2019. Vol. 42, №2.; Bachet J.-B. et al. Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: Feasibility and potential benefits in a retrospective series of 117 patients // Gastroenterol Clin Biol. 2009. Vol. 33, № 10–11.; Oettle H. et al. Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial // Journal of Clinical Oncology. 2014. Vol. 32, № 23.; Gill S. et al. PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy // Journal of Clinical Oncology. 2016. Vol. 34, № 32.; Portal A. et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort // Br J Cancer. 2015. Vol. 113, №7.; Mita N. et al. Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure // J Clin Med. 2019. Vol. 8, №6.; Tsang E.S. et al. Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer // Am J Clin Oncol. 2019. Vol. 42, № 12.; Zhang H. et al. Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience // Clin Colorectal Cancer. 2018. Vol. 17, №3.; Nguyen K.T. et al. Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer—retrospective analysis of response // J Gastrointest Oncol. 2017. Vol. 8, №3.; el Rassy E. et al. Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis // Clin Res Hepatol Gastroenterol. 2017. Vol. 41, №2.; de Jesus V.H. F. et al. Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer // Ther Adv Med Oncol. 2020. Vol. 12.; Assaf E. et al. 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma // Oncology. 2011. Vol. 80, №5–6.; Kobayashi N. et al. Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure // Medicine. 2017. Vol. 96, № 19.; Kim J.H. et al. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study // Cancer Commun. 2018. Vol. 38, №1.; Chung M.J. et al. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer // World J Gastrointest Oncol. 2018. Vol. 10, № 12.; Sawada M. et al. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer // BMC Cancer. 2020. Vol. 20, №1.; Matsumoto T. et al. FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure // Pancreas. 2020. Vol. 49, №4.; Bullock A. et al. Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma // J Gastrointest Oncol. 2017. Vol. 8, №6.; Chung K.H. et al. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy // Gut Liver. 2017. Vol. 11, №2.; Bayoglu I.V. et al. Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer // Asian Pacific Journal of Cancer Prevention. 2014. Vol. 15, № 17.; Park S.J. et al. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer // World J Gastrointest Oncol. 2019. Vol. 11, № 11.; Sonbol M.B. et al. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis // Cancer. 2017. Vol. 123, № 23.; Abbassi R., Algül H. Palliative chemotherapy in pancreatic cancer—treatment sequences // Transl Gastroenterol Hepatol. 2019. Vol. 4.; Dean A.P. et al. Gemcitabine and nab-paclitaxel retreatment as a third-line therapy following second-line FOLFIRINOX for advanced pancreatic adenocarcinoma. // Journal of Clinical Oncology. 2019. Vol. 37, № 15_suppl.; Golan T. et al. Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. // Journal of Clinical Oncology. 2021. Vol. 39, № 3_suppl. P. 378–378.; Golan T. et al. Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer // New England Journal of Medicine. 2019. Vol. 381, №4.; Marabelle A. et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study // Journal of Clinical Oncology. 2020. Vol. 38, №1.; Waddell N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer // Nature. 2015. Vol. 518, № 7540.; Humphris J.L. et al. Hypermutation In Pancreatic Cancer // Gastroenterology. W.B. Saunders, 2017. Vol. 152, №1. P. 68-74. e2.; Allen M.J. et al. Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature // J Clin Pathol. 2021. P. jclinpath-2021-207781.; Drilon A. et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children // New England Journal of Medicine. Massachusetts Medical Society, 2018. Vol. 378, №8. P. 731–739.; Doebele R.C. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials // Lancet Oncol. Lancet Publishing Group, 2020. Vol. 21, №2. P. 271–282.; Strickler J.H. et al. Sotorasib in KRAS p. G12C–Mutated Advanced Pancreatic Cancer // New England Journal of Medicine. 2023. Vol. 388, №1. P. 33–43.; Philip P.A. et al. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma // Clinical Cancer Research. 2022. Vol. 28, № 12. P. 2704–2714.; Schultheis B. et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study // Annals of Oncology. 2017. Vol. 28, № 10. P. 2429–2435.; Qin S. et al. Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial. // Journal of Clinical Oncology. 2022. Vol. 40, № 17_suppl. P. LBA4011–LBA4011.; da Cunha Santos G, Dhani N, Tu D, et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA. 3. Cancer 2010; 116: 5599–5607.; Wang JP, Wu C-Y, Yeh Y-C, et al. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget 2015; 6: 18162–18173.; Chikhareva, Y., et al. P-333 Retrospective analysis of second-line chemotherapy after Folfirinox failure in advanced pancreatic cancer. Annals of Oncology, 34, S131.; https://www.malignanttumors.org/jour/article/view/1157

Availability: https://www.malignanttumors.org/jour/article/view/1157
https://doi.org/10.18027/2224-5057-2023-13-4-60-68

Рак желудка

Authors: Н. С. Бесова, Л. В. Болотина, С. В. Гамаюнов, А. Е. Калинин, Н. А. Козлов, О. А. Малихова, С. Н. Неред, С. А. Проценко, И. С. Стилиди, М. Д. Тер-Ованесов, А. А. Трякин, В. М. Хомяков, С. С. Пирогов, М. В. Черных

Source: Malignant tumours; Том 13, № 3s2-1 (2023); 405-424 ; Злокачественные опухоли; Том 13, № 3s2-1 (2023); 405-424 ; 2587-6813 ; 2224-5057

Subject Terms: HER2, аденокарцинома желудка, аденокарцинома пищеводножелудочного перехода, лекарственная терапия, химиотерапия, трастузумаб, рамуцирумаб, ЭГДС, FISH

File Description: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1223/857; https://www.malignanttumors.org/jour/article/view/1223

Availability: https://www.malignanttumors.org/jour/article/view/1223
https://doi.org/10.18027/2224-5057-2023-13-3s2-1-405-424

Практические рекомендации по лекарственному лечению рака желудка

Authors: Н. С. Бесова, Л. В. Болотина, С. В. Гамаюнов, А. Е. Калинин, Н. А. Козлов, О. А. Малихова, С. Н. Неред, С. А. Проценко, И. С. Стилиди, М. Д. Тер-Ованесов, А. А. Трякин, В. М. Хомяков, С. С. Пирогов, М. В. Черных

Source: Malignant tumours; Том 12, № 3s2-1 (2022); 382-400 ; Злокачественные опухоли; Том 12, № 3s2-1 (2022); 382-400 ; 2587-6813 ; 2224-5057

Subject Terms: HER2, аденокарцинома желудка, аденокарцинома пищеводножелудочного перехода, лекарственная терапия, химиотерапия, трастузумаб, рамуцирумаб, ЭГДС, FISH

File Description: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1041/738; https://www.malignanttumors.org/jour/article/view/1041

Availability: https://www.malignanttumors.org/jour/article/view/1041
https://doi.org/10.18027/2224-5057-2022-12-3s2-382-400

Лекарственная терапия метастатического рака желудка

Authors: О. А. Кузнецова, М. Ю. Федянин, Г. М. Найдин, Н. С. Бесова, А. А. Трякин

Source: Malignant tumours; Том 12, № 3s1 (2022); 17-26 ; Злокачественные опухоли; Том 12, № 3s1 (2022); 17-26 ; 2587-6813 ; 2224-5057

Subject Terms: лекарственная терапия

File Description: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/996/693; Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71 (3) : 209–249. doi:10.3322/caac.21660.; SEER Cancer Statistics https://seer.cancer.gov/statfacts/html/stomach.html.; Glimelius B, Ekström K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997; 8 (2) : 163–168. doi:10.1023/a:1008243606668.; Pyrhönen S, Kuitunen T, Nyandoto P, et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995; 71 (3) : 587–591. doi:10.1038/bjc.1995.114.; Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017; 8 (8) : CD004064. Published 2017 Aug 29. doi:10.1002/14651858.CD004064.pub4.; Smyth EC, Verheij M, Allum W, et al. Gastric cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27 (suppl 5) : v38-v49. doi:10.1093/annonc/mdw350.; Muro K, Van Cutsem E, Narita Y, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer : a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019; 30 (1) : 19–33. doi:10.1093/annonc/mdy502.; Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer : a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006; 24 (18) : 2903– 2909. doi:10.1200/JCO.2005.05.0245.; Kang YK, Chin K, Chung HC, et al. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR) : a randomised, open-label, phase 3 trial. Lancet Oncol. 2020; 21 (8) : 1045–1056. doi:10.1016/S1470-2045(20)30315-6.; Montagnani F, Turrisi G, Marinozzi C, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer : a systematic review and meta-analysis. Gastric Cancer. 2011; 14 (1) : 50–55. doi:10.1007/s10120-011-0007-7.; Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358 (1) : 36–46. doi:10.1056/NEJMoa073149.; Ryu MH, Kang YK. ML17032 trial : capecitabine / cisplatin versus 5-fluorouracil / cisplatin as first-line therapy in advanced gastric cancer. Expert Rev Anticancer Ther. 2009; 9 (12) : 1745–1751. doi:10.1586/era.09.149.; Okines AFC, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials : evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009; 20 (9) : 1529– 1534. doi:10.1093/annonc/mdp047.; Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma : a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study [published correction appears in J Clin Oncol. 2015 Apr 20; 33 (12) : 1416]. J Clin Oncol. 2014; 32 (31) : 3520–3526. doi:10.1200/JCO.2013.54.1011.; Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer : a report of the V325 Study Group. J Clin Oncol. 2006; 24 (31) : 4991–4997. doi:10.1200/JCO.2006.06.8429.; Shah MA, Janjigian YY, Stoller R, et al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma : A Study of the US Gastric Cancer Consortium. J Clin Oncol. 2015; 33 (33) : 3874–3879. doi:10.1200/JCO.2015.60.7465.; Al-Batran SE, Pauligk C, Homann N, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer : a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65 +). Eur J Cancer. 2013; 49 (4) : 835–842. doi:10.1016/j.ejca.2012.09.025.; Park H, Jin RU, Wang-Gillam A, et al. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers : A Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2020; 6 (8) : 1231– 1240. doi:10.1001/jamaoncol.2020.2020.; Guo X, Zhao F, Ma X, et al. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer : a systematic review and meta-analysis. BMC Cancer. 2019; 19 (1) : 1125. Published 2019 Nov 20. doi:10.1186/s12885-019-6294-9.; Yamada Y, Boku N, Mizusawa J, et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013) : an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019; 4 (7) : 501–510. doi:10.1016/S2468-1253(19)30083-4.; Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer : a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011; 29 (30) : 3968– 3976. doi:10.1200/JCO.2011.36.2236.; Waddell T, Chau I, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3) : a randomised, open-label phase 3 trial [published correction appears in Lancet Oncol. 2013 Jun; 14 (7) : e254. Frances, Alicia [corrected to Okines, Alicia Frances Clare]]. Lancet Oncol. 2013; 14 (6) : 481–489. doi:10.1016/S14702045(13)70096-2.; Shah MA, Bang YJ, Lordick F, et al. Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma : The METGastric Randomized Clinical Trial. JAMA Oncol. 2017; 3 (5) : 620–627. doi:10.1001/jamaoncol.2016.5580.; Catenacci DVT, Tebbutt NC, Davidenko I, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18 (11) : 1467–1482. doi:10.1016/S1470-2045(17)30566-1.; Fuchs CS, Shitara K, Di Bartolomeo M, et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL) : a double-blind, randomised, placebo-controlled, phase 3 trial [published correction appears in Lancet Oncol. 2019 May; 20 (5) : e242]. Lancet Oncol. 2019; 20 (3) : 420–435. doi:10.1016/S1470-2045(18)30791-5.; Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA) : a phase 3, open-label, randomised controlled trial [published correction appears in Lancet. 2010 Oct 16; 376 (9749) : 1302]. Lancet. 2010; 376 (9742) : 687–697. doi:10.1016/S0140-6736(10)61121-X.; O’Hare, A. Highlights from the latest news and research in clinical investigation. Clin. Investig. (Lond). 2, 761–763 (2012).; Tabernero J, Hoff PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB) : final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018; 19 (10) : 1372–1384. doi:10.1016/S1470-2045(18)30481-9.; Lee HE, Park KU, Yoo SB, et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer. 2013; 49 (6) : 1448–1457. doi:10.1016/j.ejca.2012.10.018.; Lee S, de Boer WB, Fermoyle S, et al. Human epidermal growth factor receptor 2 testing in gastric carcinoma : issues related to heterogeneity in biopsies and resections. Histopathology. 2011; 59 (5) : 832–840. doi:10.1111/j.1365-2559.2011.04017.x.; Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010; 457 (3) : 299–307. doi:10.1007/s00428-010-0952-2.; Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer : results from a validation study. Histopathology. 2008; 52 (7) : 797–805. doi:10.1111/j.13652559.2008.03028.x.; Bartley AN, Washington MK, Ventura CB, et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma : Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016; 140 (12) : 1345–1363. doi:10.5858/arpa.2016-0331-CP.; Viúdez A, Carmona-Bayonas A, Gallego J, et al. Optimal duration of first-line chemotherapy for advanced gastric cancer : data from the AGAMENON registry. Clin Transl Oncol. 2020; 22 (5) : 734–750. doi:10.1007/s12094-019-02183-y.; Fanotto V, Cordio S, Pasquini G, et al. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. Gastric Cancer. 2017; 20 (5) : 825–833. doi:10.1007/s10120-016-0681-6.; Catalano V, Graziano F, Santini D, et al. Second-line chemotherapy for patients with advanced gastric cancer : who may benefit?. Br J Cancer. 2008; 99 (9) : 1402–1407. doi:10.1038/sj.bjc.6604732.; Kanagavel D, Pokataev IA, Fedyanin MY, et al. A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol. 2010; 21 (9) : 1779–1785. doi:10.1093/annonc/mdq032.; Fuchs CS, Muro K, Tomasek J, et al. Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. J Gastric Cancer. 2017; 17 (2) : 132–144. doi:10.5230/jgc.2017.17.e16.; Kanagavel D, Fedyanin M, Tryakin A, Tjulandin S. Second-line treatment of metastatic gastric cancer : Current options and future directions. World J Gastroenterol. 2015; 21 (41) : 11621–11635. doi:10.3748/wjg.v21.i41.11621.; Cotes Sanchís A, Gallego J, Hernandez R, et al. Second-line treatment in advanced gastric cancer : Data from the Spanish AGAMENON registry. PLoS One. 2020; 15 (7) : e0235848. Published 2020 Jul 31. doi:10.1371/journal.pone.0235848.; Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011; 47 (15) : 2306–2314. doi:10.1016/j.ejca.2011.06.002.; Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014; 15 (1) : 78–86. doi:10.1016/S1470-2045(13)70549-7.; Kang JH, Lee SI, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer : a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone [published correction appears in J Clin Oncol. 2012 Aug 20; 30 (24) : 3035]. J Clin Oncol. 2012; 30 (13) : 1513– 1518. doi:10.1200/JCO.2011.39.4585.; Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum : WJOG 4007 trial. J Clin Oncol. 2013; 31 (35) : 4438–4444. doi:10.1200/JCO.2012.48.5805.; Casak SJ, Fashoyin-Aje I, Lemery SJ, et al. FDA Approval Summary : Ramucirumab for Gastric Cancer. Clin Cancer Res. 2015; 21 (15) : 3372–3376. doi:10.1158/1078-0432.CCR-15-0600.; Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD) : an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014; 383 (9911) : 31–39. doi:10.1016/S01406736(13)61719-5.; Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW) : a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15 (11) : 1224–1235. doi:10.1016/S1470-2045(14)70420-6.; Xu RH, Zhang Y, Pan H, et al. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia) : a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2021; 6 (12) : 1015–1024. doi:10.1016/S24681253(21)00313-7.; Di Bartolomeo M, Niger M, Tirino G, et al. Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer : Real-World Data from the RAMoss Study. Target Oncol. 2018; 13 (2) : 227– 234. doi:10.1007/s11523-018-0562-5.; Paulson AS, Hess LM, Liepa AM, et al. Ramucirumab for the treatment of patients with gastric or gastroesophageal junction cancer in community oncology practices. Gastric Cancer. 2018; 21 (5) : 831–844. doi:10.1007/s10120-018-0796-z.; Jung M, Ryu MH, Oh DY, et al. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer. 2018; 21 (5) : 819–830. doi:10.1007/s10120-018-0806-1.; Lorenzen S, Thuss-Patience P, Pauligk C, et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel — results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. Eur J Cancer. 2022; 165 : 48–57. doi:10.1016/j.ejca.2022.01.015.; Park H, Sanjeevaiah A, Hosein P, et al., Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma : Final analysis of a phase II trial. 10.1200/JCO.2022.40.4_suppl. 284.; Tryakin A, Perminova E, Stroyakovsky D, et al. Ramucirumab in the treatment of refractory metastatic gastric cancer : Results from the RamSelGa trial. Ann. Oncol. 30, v306-v307 (2019). doi:https://doi.org/10.1093/annonc/mdz247.123.; Shitara K, Doi T, Dvorkin M, et al. Trifluridine / tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS) : a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Oncol. 2018 Dec; 19 (12) : e668]. Lancet Oncol. 2018; 19 (11) : 1437–1448. doi:10.1016/S1470-2045(18)30739-3.; Pavlakis N, Sjoquist KM, Martin AJ, et al. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE) : A Multinational Placebo-Controlled Phase II Trial. J Clin Oncol. 2016; 34 (23) : 2728–2735. doi:10.1200/JCO.2015.65.1901.; Makiyama A, Sukawa Y, Kashiwada T, et al. Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer : WJOG7112G (T-ACT Study). J Clin Oncol. 2020; 38 (17) : 1919–1927. doi:10.1200/JCO.19.03077.; Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations : TyTAN--a randomized, phase III study. J Clin Oncol. 2014; 32 (19) : 2039– 2049. doi:10.1200/JCO.2013.53.6136.; Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY) : an international randomised, open-label, adaptive, phase 2 / 3 study. Lancet Oncol. 2017; 18 (5) : 640–653. doi:10.1016/S1470-2045(17)30111-0.; Rha S, Kim C, Jung M, et al, Multicenter phase Ib / II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer : Updated HER-RAM study with biomarker analysis, 10.1200/JCO.2022.40.4_suppl.330.; Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020; 382 (25) : 2419–2430. doi:10.1056/NEJMoa2004413.; Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538–12, ATTRACTION-2) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390 (10111) : 2461–2471. doi:10.1016/S01406736(17)31827-5.; Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 Study : Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer [published correction appears in J Clin Oncol. 2019 Feb 10; 37 (5) : 443]. J Clin Oncol. 2018; 36 (28) : 2836–2844. doi:10.1200/JCO.2017.76.6212.; Fuchs CS, Doi T, Jang RW, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer : Phase 2 Clinical KEYNOTE-059 Trial [published correction appears in JAMA Oncol. 2019 Apr 1; 5 (4) : 579]. JAMA Oncol. 2018; 4 (5) : e180013. doi:10.1001/jamaoncol.2018.0013.; Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061) : a randomised, open-label, controlled, phase 3 trial. Lancet. 2018; 392 (10142) : 123–133. doi:10.1016/S01406736(18)31257-1.; Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer : The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6 (10) : 1571–1580. doi:10.1001/jamaoncol.2020.3370.; Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4) : a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022; 23 (2) : 234–247. doi:10.1016/S1470-2045(21)00692-6.; Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649) : a randomised, open-label, phase 3 trial. Lancet. 2021; 398 (10294) : 27–40. doi:10.1016/S0140-6736(21)00797-2.; Shitara, K, Janjigian, Y, Moehler, M, et al. Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer / gastroesophageal junction cancer / esophageal adenocarcinoma (GC / GEJC / EAC) : Expanded efficacy, safety, and subgroup analyses from CheckMate 649. Journal of Clinical Oncology 40, no. 4_suppl (February 01, 2022) 240–240. doi:0.1200/JCO.2022.40.4_suppl.240.; Shitara, K., Ajani, J. A., Moehler, M. et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603, 942–948 (2022). https://doi.org/10.1038/s41586022-04508-4.; Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021; 600 (7890) : 727–730. doi:10.1038/s41586-021-04161-3.; Yeong J, Lum HYJ, Teo CB, et al. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer. 2022; 25 (4) : 741–750. doi:10.1007/s10120-022-01301-0.; Zhou KI, Peterson B, Serritella A, et al. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. Clin Cancer Res. 2020; 26 (24) : 6453–6463. doi:10.1158/1078-0432.CCR-20-2085.; Chao J, Fuchs CS, Shitara K, et al. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol. 2021; 7 (6) : 895–902. doi:10.1001/jamaoncol.2021.0275.; Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability / Mismatch Repair-Deficient Cancer : Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020; 38 (1) : 1–10. doi : 10.1200/JCO.19.02105.; https://www.malignanttumors.org/jour/article/view/996

Availability: https://www.malignanttumors.org/jour/article/view/996

Comparison of the treatment results in patients with inoperable non-small cell lung cancer in clinical trials and in standard clinical practice using the pseudorandomization method ; Сравнение результатов лечения больных неоперабельным немелкоклеточным раком легкого в рамках клинических исследований и стандартной клинической практики методом псевдорандомизации

Authors: Moiseenko F.V., Fedyanin M.Y., Volkov N.M., Abduloeva N.K., Levchenko N.V., Chubenko V.A., Zhabina A.S., Stepanova M.L., Kramchaninov M.M., Artemeva E.V., Moiseyenko V.M.

Contributors: 1

Source: Almanac of Clinical Medicine; Vol 50, No 1 (2022); 47-55 ; Альманах клинической медицины; Vol 50, No 1 (2022); 47-55 ; 2587-9294 ; 2072-0505

Subject Terms: lung cancer, non-small cell lung cancer, medical treatment, clinical trials, рак легкого, немелкоклеточный рак легкого, лекарственная терапия, клинические исследования

File Description: application/pdf

Relation: https://almclinmed.ru/jour/article/view/1610/1438; https://almclinmed.ru/jour/article/view/1610/1452; https://almclinmed.ru/jour/article/downloadSuppFile/1610/2758; https://almclinmed.ru/jour/article/downloadSuppFile/1610/2759; https://almclinmed.ru/jour/article/downloadSuppFile/1610/2760; https://almclinmed.ru/jour/article/downloadSuppFile/1610/2761; https://almclinmed.ru/jour/article/downloadSuppFile/1610/2762; https://almclinmed.ru/jour/article/view/1610

Availability: https://almclinmed.ru/jour/article/view/1610
https://doi.org/10.18786/2072-0505-2022-50-004

Off-Label Drug Use in Oncology

Authors: E. V. Karabina, D. D. Sakaeva, O. N. Lipatov

Source: Креативная хирургия и онкология, Vol 12, Iss 2, Pp 164-171 (2022)

Subject Terms: использование лекарств не по прямому назначению, злокачественные новообразования, противоопухолевая лекарственная терапия, незарегистрированные препараты, противоопухолевая таргетная терапия, бевацизумаб, ритуксимаб, ингибиторы иммунных контрольных точек, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Relation: https://www.surgonco.ru/jour/article/view/698; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093; https://doaj.org/article/c3e8a83e0fd6422b816023ec39d205af

Availability: https://doi.org/10.24060/2076-3093-2022-12-2-164-171
https://doaj.org/article/c3e8a83e0fd6422b816023ec39d205af

Опыт успешного применения экстракорпоральных методов лечения синдрома лизиса опухоли ; Experience in the successful application of extracorporeal methods in treatment of tumor lysis syndrome

Authors: Voroshin, D. G., Beloborodov, V. V., Vazhenin, A. V., Ermakov, M. A., Ворошин, Д. Г., Белобородов, В. В., Важенин, А. В., Ермаков, М. А.

Subject Terms: TUMOR LYSIS SYNDROME, EXTRACORPOREAL TREATMENT METHODS, ANTITUMOR DRUG THERAPY, СИНДРОМ ЛИЗИСА ОПУХОЛИ, ЭКСТРАКОРПОРАЛЬНЫЕ МЕТОДЫ ЛЕЧЕНИЯ, ПРОТИВООПУХОЛЕВАЯ ЛЕКАРСТВЕННАЯ ТЕРАПИЯ

File Description: application/pdf

Relation: Уральский медицинский журнал. 2021. т. 20. №2; http://elib.usma.ru/handle/usma/6276

Availability: http://elib.usma.ru/handle/usma/6276

BREAST-CONSERVING SURGERY AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS ; ОРГАНОСОХРАНЯЮЩИЕ ОПЕРАЦИИ ПОСЛЕ НЕОАДЪЮВАНТНОЙ ЛЕКАРСТВЕННОЙ ТЕРАПИИ У БОЛЬНЫХ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ

Authors: A. R. Bosieva, M. V. Ermoshchenkova, N. N. Volchenko, A. D. Zikiryahodjaev, А. Р. Босиева, М. В. Ермощенкова, Н. Н. Волченко, А. Д. Зикиряходжаев

Source: Siberian journal of oncology; Том 20, № 4 (2021); 116-121 ; Сибирский онкологический журнал; Том 20, № 4 (2021); 116-121 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2021-20-4

Subject Terms: края резекции, neoadjuvant chemotherapy, breast-conserving surgery, resection margins, неоадъювантная лекарственная терапия, органосохраняющие операции

File Description: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1873/891; Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М., 2019. 250 с.; Munhoz A.M., Montag E., Gemperli R. Oncoplastic breast surgery: indications, techniques and perspectives. Gland Surg. 2013 Aug; 2(3): 143–57. doi:10.3978/j.issn.2227-684X.2013.08.02.; Исмагилов А.Х., Ванесян А.С., Хамитов А.Р., Камалетдинов И.Ф. Онкопластическая хирургия молочной железы: основы, классификация, алгоритм выполнения. Опухоли женской репродуктивной системы. 2014; 4: 37–42.; Veronesi U., Banfi A., Salvadori B., Luini A., Saccozzi R., Zucali R., Marubini E., Del Vecchio M., Boracchi P., Marchini S. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Cancer. 1990; 26(6): 668–70. doi:10.1016/0277-5379(90)90113-8.; Пак Д.Д., Рассказова Е.А. Органосохраняющие операции при раке молочной железы. Опухоли женской репродуктивной системы. 2011; 2: 22–27.; Зикиряходжаев А.Д., Чиссов В.И., Ермощенкова М.В., Сухотько А.С., Тукмаков А.Ю. Методологические аспекты и результаты онкопластических резекций молочной железы. Онкология. Журнал им. П.А. Герцена. 2016; 2(5): 4–11.; Franceschini G., Martin Sanchez A., Di Leone A., Magno S., Moschella F., Accetta C., Masetti R. New trends in breast cancer surgery: a therapeutic approach increasingly efficacy and respectful of the patient. G Chir. 2015 Jul-Aug; 36(4): 145–52. doi:10.11138/gchir/2015.36.4.145.; Ермощенкова М.В., Зикиряходжаев А.Д., Широких И.М., Тукмаков А.В., Масри А.А., Запиров М.М. Хирургическая реабилитация больных раком молочной железы на различных этапах комбинированного и комплексного лечения. Онкология. Журнал им. П.А. Герцена. 2019; 3(8): 161–169.; Fitoussi A.D., Berry M.G., Famà F., Falcou M.C., Curnier A., Couturaud B., Reyal F., Salmon R.J. Oncoplastic breast surgery for cancer: analysis of 540 consecutive cases [outcomes article]. Plast Reconstr Surg. 2010 Feb; 125(2): 454–462. doi:10.1097/PRS.0b013e3181c82d3e.; Asgeirsson K.S., Rasheed T., McCulley S.J., Macmillan R.D. Oncological and cosmetic outcomes of oncoplastic breast conserving surgery. Eur J Surg Oncol. 2005 Oct; 31(8): 817–23. doi:10.1016/j.ejso.2005.05.010.; Chen A.M., Meric-Bernstam F., Hunt K.K., Thames H.D., Oswald M.J., Outlaw E.D., Buchholz T.A. Breast conservation after neoadjuvant chemotherapy: The M.D. Anderson cancer center experience. J Clin Oncol. 2004; 12(22): 2303–12.; Boughey J.C., Peintinger F., Meric-Bernstam F., Perry A.C., Hunt K.K., Babiera G.V., Singletary S.E., Bedrosian I., Lucci A., Buzdar A.U., Pusztai L., Kuerer H.M. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006 Sep; 244(3): 464–70. doi:10.1097/01.sla.0000234897.38950.5c.; Mazouni C., Naveau A., Kane A., Dunant A., Garbay J.R., Leymarie N., Sarfati B., Delaloge S., Rimareix F. The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy. Breast. 2013 Dec; 22(6): 1189–93. doi:10.1016/j.breast.2013.07.055.; Silverstein M.J., Savalia N., Khan S., Ryan J. Extreme oncoplasty: breast conservation for patients who need mastectomy. Breast J. 2015 JanFeb; 21(1): 52–9. doi:10.1111/tbj.12356.; Koppiker C.B., Noor A.U., Dixit S., Busheri L., Sharan G., Dhar U., Allampati H.K., Nare S. Extreme Oncoplastic Surgery for Multifocal/ Multicentric and Locally Advanced Breast Cancer. Int J Breast Cancer. 2019 Feb 20; 2019: 4262589. doi:10.1155/2019/4262589.; Pearce B.C.S., Fiddes R.N., Paramanathan N., Chand N., Laws S.A.M., Rainsbury R.M. Extreme oncoplastic conservation is a safe new alternative to mastectomy. Eur J Surg Oncol. 2020; 46(1): 71–76. doi:10.1016/j.ejso.2019.09.004.; Curigliano G., Burstein H.J., Winer E.P., Gnant M., Dubsky P., Loibl S., Colleoni M., Regan M.M., Piccart-Gebhart M., Senn H.J., Thürlimann B.; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F., Baselga J., Bergh J., Bonnefoi H., Brucker S.Y., Cardoso F., Carey L., Ciruelos E., Cuzick J., Denkert C., Di Leo A., Ejlertsen B., Francis P., Galimberti V., Garber J., Gulluoglu B., Goodwin P., Harbeck N., Hayes D.F., Huang C.S., Huober J., Hussein K., Jassem J., Jiang Z., Karlsson P., Morrow M., Orecchia R., Osborne K.C., Pagani O., Partridge A.H., Pritchard K., Ro J., Rutgers E.J.T., Sedlmayer F., Semiglazov V., Shao Z., Smith I., Toi M., Tutt A., Viale G., Watanabe T., Whelan T.J., Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017; 28(8): 1700–12. doi:10.1093/annonc/mdx308.; Choi J., Laws A., Hu J., Barry W., Golshan M., King T. Margins in Breast-Conserving Surgery After Neoadjuvant Therapy. Ann Surg Oncol. 2018 Nov; 25(12): 3541–3547. doi:10.1245/s10434-018-6702-4.; Rouzier R., Extra J.M., Carton M., Falcou M.C., Vincent-Salomon A., Fourquet A., Pouillart P., Bourstyn E. Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol. 2001 Sep 15; 19(18): 3828–35. doi:10.1200/JCO.2001.19.18.3828.; Valachis A., Mamounas E.P., Mittendorf E.A., Hayashi N., Ishitobi M., Natoli C., Fitzal F., Rubio I.T., Tiezzi D.G., Shin H.C., Anderson S.J., Hunt K.K., Matsuda N., Ohsumi S., Totomi A., Nilsson C. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. Cancer. 2018; 124(14): 2923–30. doi:10.1002/cncr.31518.; Mamounas E.P., Anderson S.J., Dignam J.J., Bear H.D., Julian T.B., Geyer C.E.Jr., Taghian A., Wickerham D.L., Wolmark N. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012 Nov 10; 30(32): 3960–6. doi:10.1200/JCO.2011.40.8369.; Mauri D., Pavlidis N., Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97(3): 188–94. doi:10.1093/jnci/dji021.; Mieog J.S., van der Hage J.A., van de Velde C.J. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007; 94(10): 1189–200. doi:10.1002/bjs.5894.; Volders J.H., Haloua M.H., Krekel N.M., Negenborn V.L., Barbé E., Sietses C., Jóźwiak K., Meijer S., van den Tol M.P.; the nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA). Neoadjuvant chemotherapy in breast-conserving surgery – Consequences on margin status and excision volumes: A nationwide pathology study. Eur J Surg Oncol. 2016 Jul; 42(7): 986–93. doi:10.1016/j.ejso.2016.02.252.; https://www.siboncoj.ru/jour/article/view/1873

Availability: https://www.siboncoj.ru/jour/article/view/1873
https://doi.org/10.21294/1814-4861-2021-20-4-116-121

SYSTEMATIC REVIEW AND METAANALYSIS OF THE RESULTS OF BREAST-CONSERVING SURGERY AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS ; СИСТЕМАТИЧЕСКИЙ ОБЗОР И МЕТААНАЛИЗ РЕЗУЛЬТАТОВ ОРГАНОСОХРАНЯЮЩИХ ОПЕРАЦИЙ ПОСЛЕ НЕОАДЪЮВАНТНОЙ ЛЕКАРСТВЕННОЙ ТЕРАПИИ У БОЛЬНЫХ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ

Authors: A. R. Bosieva, M. V. Ermoshchenkova, A. D. Zikiryakhodzhayev, N. N. Volchenko, А. Р. Босиева, М. В. Ермощенкова, А. Д. Зикиряходжаев, Н. Н. Волченко

Source: Siberian journal of oncology; Том 20, № 2 (2021); 118-126 ; Сибирский онкологический журнал; Том 20, № 2 (2021); 118-126 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2021-20-2

Subject Terms: косметические результаты, neoadjuvant chemotherapy, breast-conserving surgery, margin status, volume of tissue removed, cosmetic outcomes, неоадъювантная лекарственная терапия, органосохраняющие операции, края резекции, ререзекция, объем удаляемых тканей, рецидив

File Description: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/1764/855; Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М., 2019. с. 250.; Mieog J.S., van der Hage J.A., van de Velde C.J. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007 Apr 18; 2007(2): CD005002. doi:10.1002/14651858.CD005002.pub2.; Mittendorf E.A., Buchholz T.A., Tucker S.L., Meric-Bernstam F., Kuerer H.M., Gonzalez-Angulo A.M., Bedrosian I., Babiera G.V., Hoffman K., Yi M., Ross M.I., Hortobagyi G.N., Hunt K.K. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg. 2013; 257(2): 173–9. doi:10.1097/SLA.0b013e3182805c4a.; Mauri D., Pavlidis N., Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005 Feb 2; 97(3): 188–94. doi:10.1093/jnci/dji021.; Curran D., van Dongen J.P., Aaronson N.K., Kiebert G., Fentiman I.S., Mignolet F., Bartelink H. Quality of life of early- stage breast cancer patients treated with radical mastectomy or breast-conserving procedures: results of EORTC Trial 10801. The European Organization for Research and Treatment of Cancer (EORTC), Breast Cancer Co-operative Group (BCCG). Eur J Cancer. 1998 Feb; 34(3): 307–14. doi:10.1016/s0959-8049(97)00312-2.; Kim M.K., Kim T., Moon H.G., Jin U.S., Kim K., Kim J., Lee J.W., Kim J., Lee E., Yoo T.K., Noh D.Y., Minn K.W., Han W. Effect of cosmetic outcome on quality of life after breast cancer surgery. Eur J Surg Oncol. 2015 Mar; 41(3): 426–32. doi:10.1016/j.ejso.2014.12.002.; Arndt V., Stegmaier C., Ziegler H., Brenner H. Quality of life over 5 years in women with breast cancer after breast-conserving therapy versus mastectomy: a population-based study. J Cancer Res Clin Oncol. 2008 Dec; 134(12): 1311–8. doi:10.1007/s00432-008-0418-y.; Jagsi R., Li Y., Morrow M., Janz N., Alderman A., Graff J., Hamilton A., Katz S., Hawley S. Patient-reported Quality of Life and Satisfaction With Cosmetic Outcomes After Breast Conservation and Mastectomy With and Without Reconstruction: Results of a Survey of Breast Cancer Survivors. Ann Surg. 2015 Jun; 261(6): 1198–206. doi:10.1097/SLA.0000000000000908.; Markopoulos C., Tsaroucha A.K., Kouskos E., Mantas D., Antonopoulou Z., Karvelis S. Impact of breast cancer surgery on the self-esteem and sexual life of female patients. J Int Med Res. 2009 Jan-Feb; 37(1): 182–8. doi:10.1177/147323000903700122.; Vrieling C., Collette L., Fourquet A., Hoogenraad W.J., Horiot J.H., Jager J.J., Pierart M., Poortmans P.M., Struikmans H., Maat B., Van Limbergen E., Bartelink H. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol. 2000; 55(3): 219–32. doi:10.1016/s0167-8140(00)00210-3.; Immink J.M., Putter H., Bartelink H., Cardoso J.S., Cardoso M.J., van der Hulst-Vijgen M.H.V., Noordijk E.M., Poortmans P.M., Rodenhuis C.C., Struikmans H. Long-term cosmetic changes after breast-conserving treatment of patients with stage I-II breast cancer and included in the EORTC ‘boost versus no boost’ trial. Ann Oncol. 2012 Oct; 23(10): 2591–98. doi:10.1093/annonc/mds066.; Cochrane R.A., Valasiadou P., Wilson A.R., Al-Ghazal S.K., Macmillan R.D. Cosmesis and satisfaction after breast- conserving surgery correlates with the percentage of breast volume excised. Br J Surg. 2003 Dec; 90(12): 1505–9. doi:10.1002/bjs.4344.; Taylor M.E., Perez C.A., Halverson K.J., Kuske R.R., Philpott G.W., Garcia D.M., Mortimer J.E., Myerson R.J., Radford D., Rush C. Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys. 1995 Feb 15; 31(4): 753–64. doi:10.1016/0360-3016(94)00480-3.; Hennigs A., Hartmann B., Rauch G., Golatta M., Tabatabai P., Domschke C., Schott S., Schütz F., Sohn C., Heil J. Long-term objective esthetic outcome after breast-conserving therapy. Breast Cancer Res Treat. 2015 Sep; 153(2): 345–51. doi:10.1007/s10549-015-3540-y.; Haloua M.H., Volders J.H., Krekel N.M., Lopes Cardozo A.M., de Roos W.K., de Widt-Levert L.M., van der Veen H., Rijna H., Bergers E., Jóźwiak K., Meijer S., van den Tol P. Intraoperative Ultrasound Guidance in Breast-Conserving Surgery Improves Cosmetic Outcomes and Patient Satisfaction: Results of a Multicenter Randomized Controlled Trial (COBALT). Ann Surg Oncol. 2016; 23(1): 30–7. doi:10.1245/s10434-015-4906-4.; Parvez E., Cornacchi S.D., Hodgson N., Thoma A., Kong I., Foster G., Cheng J., Goldsmith C.H., Dao D., Lovrics P.J. A cosmesis outcome substudy in a prospective, randomized trial comparing radioguided seed localization with standard wire localization for nonpalpable, invasive, and in situ breast carcinomas. Am J Surg. 2014 Nov; 208(5): 711–8. doi:10.1016/j.amjsurg.2014.05.030.; King T.A., Morrow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol. 2015 Jun; 12(6): 335–43. doi:10.1038/nrclinonc.2015.63.; Bossuyt V., Provenzano E., Symmans W.F., Boughey J.C., Coles C., Curigliano G., Dixon J.M., Esserman L.J., Fastner G., Kuehn T., Peintinger F., von Minckwitz G., White J., Yang W., Badve S., Denkert C., MacGrogan G., Penault-Llorca F., Viale G., Cameron D.; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol. 2015 Jul; 26(7): 1280–91. doi:10.1093/annonc/mdv161.; Mukhtar R.A., Yau C., Rosen M., Tandon V.J.; I-SPY 1 TRIAL and ACRIN 6657 Investigators, Hylton N., Esserman L.J. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2013 Nov; 20(12): 3823–30. doi:10.1245/s10434-013-3038-y.; Howick J., Chalmers I., Glasziou P. The Oxford 2011 levels of evidence. Oxford centre evidence-based medicine. 2011. 11.; Boughey J.C., Peintinger F., Meric-Bernstam F., Perry A.C., Hunt K.K., Babiera G.V., Singletary S.E., Bedrosian I., Lucci A., Buzdar A.U., Pusztai L., Kuerer H.M. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006 Sep; 244(3): 464–70. doi:10.1097/01.sla.0000234897.38950.5c.; Waljee J.F., Hu E.S., Newman L.A., Alderman A.K. Predictors of re-excision among women undergoing breast-conserving surgery for cancer. Ann Surg Oncol. 2008 May; 15(5): 1297–303. doi:10.1245/s10434-007-9777-x.; Komenaka I.K., Hibbard M.L., Hsu C.H., Low B.G., Salganick J.A., Bouton M.E., Jha C. Preoperative chemotherapy for operable breast cancer improves surgical outcomes in the community hospital setting. Oncologist. 2011; 16(6): 752–9. doi:10.1634/theoncologist.2010-0268.; Karanlik H., Ozgur I., Cabioglu N., Sen F., Erturk K., Kilic B., Onder S., Deniz M., Yavuz E., Aydiner A. Preoperative chemotherapy for T2 breast cancer is associated with improved surgical outcome. Eur J Surg Oncol. 2015 Sep; 41(9): 1226–33. doi:10.1016/j.ejso.2015.06.003.; Christy C.J., Thorsteinsson D., Grube B.J., Black D., Abu-Khalaf M., Chung G.G., DiGiovanna M.P., Miller K., Higgins S.A., Weidhaas J., Harris L., Tavassoli F.A., Lannin D.R. Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter. Ann Surg Oncol. 2009 Mar; 16(3): 697–702. doi:10.1245/s10434-008-0268-5.; Kryh C.G., Pietersen C.A., Rahr H.B., Christensen R.D., Wamberg P., Lautrup M.D. Re-resection rates and risk characteristics following breast conserving surgery for breast cancer and carcinoma in situ: A single-centre study of 1575 consecutive cases. Breast. 2014; 23(6): 784–9. doi:10.1016/j.breast.2014.08.011.; Tiezzi D.G., Andrade J.M., Marana H.R., Zola F.E., Peria F.M. Breast conserving surgery after neoadjuvant therapy for large primary breast cancer. Eur J Surg Oncol. 2008 Aug; 34(8): 863–7. doi:10.1016/j.ejso.2008.01.015.; Amabile M.I., Mazouni C., Guimond C., Sarfati B., Leymarie N., Cloutier A.S., Bentivegna E., Garbay J.R., Kolb F., Rimareix F. Factors Predictive of Re-excision After Oncoplastic Breast-conserving Surgery. Anticancer Res. 2015 Jul; 35(7): 4229–34.; Volders J.H., Haloua M.H., Krekel N.M., Negenborn V.L., Barbé E., Sietses C., Jóźwiak K., Meijer S., van den Tol M.P. Neoadjuvant chemotherapy in breast-conserving surgery Consequences on margin status and excision volumes: A nationwide pathology study. Eur J Surg Oncol. 2016 Jul; 42(7): 986–93. doi:10.1016/j.ejso.2016.02.252.; Sadetzki S., Oberman B., Zipple D., Kaufman B., Rizel S., Novikov I., Papa M.Z. Breast conservation after neoadjuvant chemotherapy. Ann Surg Oncol. 2005 Jun; 12(6): 480–7. doi:10.1245/ASO.2005.07.021.; Fukutomi T. Clinical practice and outcome of breast-conserving treatment: the effectiveness of preoperative systemic chemotherapy. Breast Cancer. 2006; 13(2): 147–51. doi:10.2325/jbcs.13.147.; Straver M.E., Rutgers E.J., Rodenhuis S., Linn S.C., Loo C.E., Wesseling J., Russell N.S., Oldenburg H.S., Antonini N., Vrancken Peeters M.T. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol. 2010; 17(9): 2411–8. doi:10.1245/s10434-010-1008-1.; van Riet Y.E., Maaskant A.J., Creemers G.J., van Warmerdam L.J., Jansen F.H., van de Velde C.J., Rutten H.J., Nieuwenhuijzen G.A. Identification of residual breast tumour localization after neo-adjuvant chemotherapy using a radioactive 125 Iodine seed. Eur J Surg Oncol. 2010 Feb; 36(2): 164–9. doi:10.1016/j.ejso.2009.10.009.; Gobardhan P.D., de Wall L.L., van der Laan L., ten Tije A.J., van der Meer D.C., Tetteroo E., Poortmans P.M., Luiten E.J. The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy. Ann Oncol. 2013; 24(3): 668–73. doi:10.1093/annonc/mds475.; Mazouni C., Naveau A., Kane A., Dunant A., Garbay J.R., Leymarie N., Sarfati B., Delaloge S., Rimareix F. The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy. Breast. 2013 Dec; 22(6): 1189–93. doi:10.1016/j.breast.2013.07.055.; Donker M., Drukker C.A., Valdés Olmos R.A., Rutgers E.J., Loo C.E., Sonke G.S., Wesseling J., Alderliesten T., Vrancken Peeters M.J. Guiding breast-conserving surgery in patients after neoadjuvant systemic therapy for breast cancer: a comparison of radioactive seed localization with the ROLL technique. Ann Surg Oncol. 2013; 20(8): 2569–75. doi:10.1245/s10434-013-2921-x.; Gerber B., von Minckwitz G., Eidtmann H., Rezai M., Fasching P., Tesch H., Eggemann H., Schrader I., Kittel K., Hanusch C., Solbach C., Jackisch C., Kunz G., Blohmer J.U., Huober J., Hauschild M., Nekljudova V., Loibl S., Untch M. Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44). Ann Surg Oncol. 2014 Aug; 21(8): 2517–24. doi:10.1245/s10434-014-3606-9.; Ramos M., Díez J.C., Ramos T., Ruano R., Sancho M., GonzálezOrús J.M. Intraoperative ultrasound in conservative surgery for nonpalpable breast cancer after neoadjuvant chemotherapy. Int J Surg. 2014; 12(6): 572–7. doi:10.1016/j.ijsu.2014.04.003.; Truin W., Vugts G., Roumen R.M., Maaskant-Braat A.J., Nieuwenhuijzen G.A., van der Heiden-van der Loo M., Tjan- Heijnen V.C., Voogd A.C. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer. Ann Surg Oncol. 2016 Jan; 23(1): 51–7. doi:10.1245/s10434-015-4603-3.; Rubio I.T., Esgueva-Colmenarejo A., Espinosa-Bravo M., Salazar J.P., Miranda I., Peg V. Intraoperative Ultrasound-Guided Lumpectomy Versus Mammographic Wire Localization for Breast Cancer Patients After Neoadjuvant Treatment. Ann Surg Oncol. 2016 Jan; 23(1): 38–43. doi:10.1245/s10434-015-4935-z.; Chauhan A., Sharma M.M., Kumar K. Evaluation of Surgical Outcomes of Oncoplasty Breast Surgery in Locally Advanced Breast Cancer and Comparison with Conventional Breast Conservation Surgery. Indian J Surg Oncol. 2016 Dec; 7(4): 413–419. doi:10.1007/s13193-016-0549-6.; Peintinger F., Symmans W.F., Gonzalez-Angulo A.M., Boughey J.C., Buzdar A.U., Yu T.K., Hunt K.K., Singletary S.E., Babiera G.V., Lucci A., Meric-Bernstam F., Kuerer H.M. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2006 Sep 15; 107(6): 1248–54. doi:10.1002/cncr.22111.; Espinosa-Bravo M., Sao Avilés A., Esgueva A., Córdoba O., Rodriguez J., Cortadellas T., Mendoza C., Salvador R., Xercavins J., Rubio I.T. Breast conservative surgery after neoadjuvant chemotherapy in breast cancer patients: comparison of two tumor localization methods. Eur J Surg Oncol. 2011 Dec; 37(12): 1038–43. doi:10.1016/j.ejso.2011.08.136.; Carrara G.F., Scapulatempo-Neto C., Abrahão-Machado L.F., Brentani M.M., Nunes J.S., Folgueira M.A., Vieira R.A. Breast- conserving surgery in locally advanced breast cancer submitted to neoadjuvant chemotherapy. Safety and effectiveness based on ipsilateral breast tumor recurrence and long-term follow-up. Clinics (Sao Paulo). 2017; 72(3): 134–42. doi:10.6061/clinics/2017(03)02.; Choi J., Laws A., Hu J., Barry W., Golshan M., King T. Margins in Breast-Conserving Surgery After Neoadjuvant Therapy. Ann Surg Oncol. 2018 Nov; 25(12): 3541–3547. doi:10.1245/s10434-018-6702-4.; Li X., Dai D., Chen B., Tang H., Wei W. Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis. World J Surg Oncol. 2017 Nov 28; 15(1): 210. doi:10.1186/s12957-017-1273-6.; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018 Jan; 19(1): 27–39. doi:10.1016/S1470-2045(17)30777-5.; Зикиряходжаев А.Д., Волченко Н.Н., Рассказова Е.А., Ермощенкова М.В., Сухотько А.С., Фетисова Е.Ю. Оценка краев резекции при органосохраняющих операциях при раке молочной железы. Онкология. Журнал им. П.А. Герцена. 2015; 4(5): 4–7.; Volders J.H., Negenborn V.L., Spronk P.E., Krekel N.M.A., Schoonmade L.J., Meijer S., Rubio I.T., van den Tol M.P. Breast-conserving surgery following neoadjuvant therapy a systematic review on surgical outcomes. Breast Cancer Res Treat. 2018 Feb; 168(1): 1–12. doi:10.1007/s10549-017-4598-5.; https://www.siboncoj.ru/jour/article/view/1764

Availability: https://www.siboncoj.ru/jour/article/view/1764
https://doi.org/10.21294/1814-4861-2021-20-2-118-126

Treatment of ankylosing spondylitis during pregnancy ; Лекарственная терапия анкилозирующего спондилита во время беременности

Authors: O. A. Krichevskaya, T. V. Dubinina, E. V. Ilinykh, S. I. Glukhova, A. B. Demina, О. А. Кричевская, Т. В. Дубинина, Е. В. Ильиных, С. И. Глухова, А. Б. Дёмина

Contributors: Исследование проводилось в рамках выполнения научной темы № 398 «Патогенетические особенности и персонифицированная терапия анкилозирующего спондилита и псориатического артрита», утвержденной Ученым советом ФГБНУ НИИР им. В.А. Насоновой. Авторы несут полную ответственность за предоставление окончательной версии рукописи в печать.

Source: Rheumatology Science and Practice; Vol 59, No 3 (2021); 288-295 ; Научно-практическая ревматология; Vol 59, No 3 (2021); 288-295 ; 1995-4492 ; 1995-4484

Subject Terms: ингибиторы ФНО-α, pregnancy, nonsteroidal anti-inflammatory drugs, TNF-α inhibitors, беременность, лекарственная терапия, нестероидные противовоспалительные препараты

File Description: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3040/2094; Ушкалова ЕА, Ткачева ОН, Чухарева НА. Проблема безопасности применения лекарственных средств во время беременности и кормления грудью. Акушерство и гинекология. 2011;(2):4-7.; Гандалоева ЗМ, Кричевская ОА, Глухова СИ, Дубинина ТВ, Лила АМ, и др. Беременность при анкилозирующем спондилите: взгляд пациентки и врача. Современная ревматология. 2019;13(1):71-79. doi:10.14412/1996-7012-2019-1-71-79; Gotestam Skorpen C, Hoeltzenbein M, Tincani A, FischerBetz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795810. doi:10.1136/annrheumdis-2015-208840; Кошелева НМ. Планирование беременности и наблюдение за беременными с ревматическими заболеваниями. В кн.: Насонов ЕЛ (ред.). Российские клинические рекомендации. Ревматология. М.:ГЭОТАР-Медиа;2017:380-389.; Tincani A, Taylor P, Fischer-Betz R, Ecoffet C, Chakravarty E. Fears and misconceptions of women with chronic rheumatic diseases on their journey to motherhood. Ann Rheum Dis. 2018;77(Suppl):A866. doi:10.1136/annrheumdis-2018-eular.2063; Haroun T, Eudy AM, Jayasundara M, Nowell WB, Curtis JR, White CW, et al. Tough choices: Understanding the medication decision-making process for women with inflammatory arthritis during pregnancy and lactation. ACR/ARHP Annual Meeting. San Diego, CA;2017 Nov 3-8, 2017:Abstract 1298.; Smolen JS, Gladman D, McNeil HP, Mease PJ, Sieper J, Hojnik M, et al. Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: A large crosssectional study. RMD Open 2019;5:e000585. doi:10.1136/rmdopen-2017-000585; Michetti P, Weinman J, Mrowietz U, Smolen J, Peyrin-Biroulet L, Louis E, et al. Impact of treatment-related beliefs on medication adherence in immune-mediated inflammatory diseases: Results of the global ALIGN study. Adv Ther. 2017;34(1):91-108. doi:10.1007/s12325-016-0441-3; van den Brandt S, Zbinden A, Baeten D, Villiger PM, Østensen M, Förger F. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. Arthritis Res Ther. 2017;19(1):64. doi:10.1186/s13075-017-1269-1; Genest G, Spitzer KA, Laskin CA. Maternal and fetal outcomes in a cohort of patients exposed to tumor necrosis factor inhibitors throughout pregnancy. J Rheumatol. 2018;45(8):1109-1115. doi:10.3899/jrheum.171152; Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, BurgosVargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: A guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(2):ii1-ii44. doi:10.1136/ard.2008.104018; Dougados M. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis. 2011;70:249-251. doi:10.1136/ard.2010.133488; Shalansky SJ, Levy AR, Ignaszewski AP. Self-reported Morisky score for identifying nonadherence with cardiovascular medications. Ann Pharmacother. 2004;38:1363-1368.; Ostensen M, Husby G. A prospective clinical study of the effect of pregnancy on rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum. 1983;26(9):1155-1159.; Timur H, Tokmak A, Turkmen GG, Ali İnal H, Uygur D, Danışman N. Pregnancy outcome in patients with ankylosing spondylitis. J Matern Fetal Neonatal Med. 2016;29(15):2470-2474. doi:10.3109/14767058.2015.1089432; Ursin K, Lydersen S, Skomsvoll JF, Wallenius M. Disease activity during and after pregnancy in women with axial spondyloarthritis: A prospective multicentre study. Rheumatology (Oxford). 2018;57(6):1064-1071. doi:10.1093/rheumatology/key047; Zbinden A, van den Brandt S, Ostensen M, Villiger PM, Förger F. Risk for adverse pregnancy outcome in axial spondyloarthritis and rheumatoid arthritis: Disease activity matters. Rheumatology. 2018;57:1235-1242. doi:10.1093/rheumatology/key053; Smith CJF, Bandoli G, Kavanaugh A, Chambers CD. Birth outcomes and disease activity during pregnancy in a prospective cohort of women with psoriaric arthritis and ankylosing spondylitis. Arthritis Care Res (Hoboken). 2020;72(7):1029-1037. doi:10.1002/acr.23924; Кричевская ОА, Гандалоева ЗМ, Дубинина ТВ. Анкилозирующий спондилит и беременность: Современный взгляд на проблему. Современная ревматология. 2018;12(3):19-28. doi:10.14412/1996-7012-2018-3-19-28

Availability: https://rsp.mediar-press.net/rsp/article/view/3040
https://doi.org/10.47360/1995-4484-2021-288-295

Treatment Strategy Options in Inoperable Chronic Thromboembolic Pulmonary Hypertension Patients ; Принципы выбора лечебной стратегии у пациентов с неоперабельной формой хронической тромбоэмболической легочной гипертензии

Authors: N. Marukyan V., M. Simakova A., D. Zubarev D., O. Moiseeva M., Н. Марукян В., М. Симакова А., Д. Зубарев Д., О. Моисеева М.

Contributors: The publication of the article is supported by Bayer, JSC, Публикация статьи поддержана компанией АО «БАЙЕР»

Source: Rational Pharmacotherapy in Cardiology; Vol 17, No 2 (2021); 278-285 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 2 (2021); 278-285 ; 2225-3653 ; 1819-6446

Subject Terms: chronic thromboembolic pulmonary hypertension, riociguat, medical therapy, баллонная ангиопластика, хроническая тромбоэмболическая легочная гипертензия, риоцигуат, лекарственная терапия

File Description: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2438/2150; Lang IM, Dorfmuller P, Vonk Noordegraaf A. The pathobiology of chronic thromboembolic pulmonary hypertension. Ann Am Thorac Soc. 2016;13 Suppl 3:S215-21. DOI:10.1513/AnnalsATS.201509-620AS.; Kim NH. Group 4 Pulmonary Hypertension: Chronic thromboembolic pulmonary hypertension: epidemiology, pathophysiology, and treatment. Cardiol Clin. 2016;34(3):435-41. DOI:10.1016/j.ccl.2016.04.011.; Feinstein JA, Goldhaber SZ, Lock JE, et al. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation. a2001;103:10-3. DOI:10.1161/01.cir.103.1.10; Ogawa A, Matsubara H. Balloon Pulmonary Angioplasty: A Treatment Option for Inoperable Patients with Chronic Thromboembolic Pulmonary Hypertension. Front Cardiovasc Med. 2015;2:4. DOI:10.3389/fcvm.2015.00004.; Чернявский А.М., Новикова Н.В., Едемский А.Г., и др. Хроническая тромбоэмболическая легочная гипертензия: сложные аспекты диагностики и лечения. Медицинский Алфавит. 2015;2(10):5-9.; Марукян Н.В., Симакова М.А., Зверев Д.А., и др. Реперфузионный отек легкого как осложнение баллонной ангиопластики легочной артерии у пациентов с хронической тромбоэмболической легочной гипертензией. Флебология. 2017;11(4):243-8. DOI:10.17116/flebo2017114243-248.; Nazzareno G, Humbert M, Vachieryc JL, et al. ESC/ERS Guideline for the diagnosis and treatment of pulmonary hypertension 2015. Eur Heart J. 2016;37(1):67-119. DOI:10.1093/eurheartj/ehv317.; Легочная гипертензия. Клинические рекомендации. Министерство Здравоохранения Российской Федерации (2020). Доступно из: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_LG.pdf]; Moradi F, Morris TA, Hoh CK. Perfusion Scintigraphy in Diagnosis and Management of Thromboembolic Pulmonary Hypertension. Radiographics. 2019;39(1):169-185. DOI:10.1148/rg.2019180074.; Castaner E, Alguersuari A, Andreu M, et al. Imaging findings in pulmonary vasculitis. Semin Ultrasound CT MR. 2012;33:567-79. DOI:10.1053/j.sult.2012.05.001.; Nawaz A, Litt HI, Stavropoulos SW, et al. Digital subtraction pulmonary arteriography versus multidetector CT in the detection of pulmonary arteriovenous malformations. J Vasc Interv Radiol. 2008;19:1582-8. DOI:10.1016/j.jvir.2008.07.011.; Madani MM. Surgical treatment of chronic thromboembolic pulmonary hypertension: pulmonary thromboendarterectomy. Methodist Debakey Cardiovasc J. 2016;12(4):213-8. DOI:10.14797/mdcj-12-4-213.; Mizoguchi H, Ogawa A, Munemasa M, et al. Refined Balloon Pulmonary Angioplasty for Inoperable Patients with Chronic Thromboembolic Pulmonary Hypertension. Circ Cardiovasc Interv. 2012;5:748- 55. DOI:10.1161/CIRCINTERVENTIONS.112.971077.; Fukui S, Ogo T, Goto Y, et al. Exercise intolerance and ventilatory inefficiency improve early after balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2015;180:66-8. DOI:10.1016/j.ijcard.2014.11.187.; Ogawa A, Matsubara H. After the Dawn - Balloon Pulmonary Angioplasty for Patients With Chronic Thromboembolic Pulmonary Hypertension. Circ J. 2018;82:1222-30. DOI:10.1253/circj.CJ-18-0258.; Olsson KM, Wiedenroth CB, Kamp JC, et al. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. Eur Respir J. 2017;49:1602409. DOI:10.1183/13993003.02409-2016.; Brenot P, Jais X, Taniguchi Y, et al. French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53:1802095. DOI:10.1183/13993003.02095-2018.; D'Armini AM, Morsolini M, Mattiucci G, et al. Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg. 2014;148:1005-11. DOI:10.1016/j.jtcvs.2014.06.052.; Kawakami T, Ogawa A, Miyaji K, et al. Novel Angiographic Classification of Each Vascular Lesion in Chronic Thromboembolic Pulmonary Hypertension Based on Selective Angiogram and Results of Balloon Pulmonary Angioplasty. Circ Cardiovasc Interv. 2016;9:e003318. DOI:10.1161/CIRCINTER-VENTIONS.115.003318.; Shimura N, Kataoka M, Inami T, Yanagisawa R, et al. Additional percutaneous transluminal pulmonary angioplasty for residual or recurrent pulmonary hypertension after pulmonary endarterectomy. Int J Cardiol. 2015;183:138-42. DOI:10.1016/j.ijcard.2015.01.034.; Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53:1801915. DOI:10.1183/13993003.01915-2018.; Ikeda N, Amemiya K, Sato S. Evolution of patients with chronic thromboembolic pulmonary hypertension treated by balloon pulmonary angioplasty, according to their anticoagulant regimens Heart Vessels. 2021 Feb 13. DOI:10.1007/s00380-021-01799-x; Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416-20. DOI:10.1056/NEJM199411243312104.; Darocha S, Banaszkiewicz M, Pietrasik A. Changes in Estimated Glomerular Filtration after Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. Cardiorena Med. 2020;10(1):22-31. DOI:10.1159/000502254.; Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369:319-29. DOI:10.1056/NEJMoa1209657.; Simonneau G, D'Armini AM, Ghofrani HA, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J. 2015;45(5):1293-302. DOI:10.1183/09031936.00087114.; Delcroix M, Torbicki A, Gopalan D, et al. ERS Statement on Chronic Thromboembolic Pulmonary Hypertension. Eur Respir J. 2020 Dec 17;2002828. DOI:10.1183/13993003.02828-2020.; Wiedenroth CB, Ghofrani HA, Miriam SD, et al. Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulmonary Circulation. 2018;8(3):1-7. DOI:10.1177/2045894018783996.; J. Ueda et al. P2597. Riociguat as a bridge therapy for balloon pulmonary angioplasty in patients with severe chronic thromboembolic pulmonary hypertension. Eur Heart J. 2017;38(suppl_1): ehx502.P2597. DOI:10.1093/eurheartj/ehx502.P2597.; Kawakami T, Matsubara H, Abe K, et al. Multicentre randomised controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: protocol for the MR BPA study. BMJ Open. 2020;10(2):e028831. DOI:10.1136/bmjopen-2018-028831.; Данилов Н.М., Матчин Ю.Г., Мартынюк Т.В. и др. Транслюминальная баллонная ангиопластика легочных артерий у больных с неоперабельной хронической тромбоэмболической легочной гипертензией (первый опыт в России). Consilium Medicum. 2015;10:61-6. DOI:10.24022/0236-2791-2020-62-4-334-344.; Inami T, Kataoka M, Shimura N, et al. Pulmonary Edema Predictive Scoring Index (PEPSI), a new index to predict risk of reperfusion pulmonary edema and improvement of hemodynamics in percutaneous transluminal pulmonary angioplasty. JACC Cardiovasc Interv. 2013;6(7):725-36. DOI:10.1016/j.jcin.2013.03.009.; Inami T, Kataoka M, Shimura N, et al. Pressure-wire-guided percutaneous transluminal pulmonary angioplasty a breakthrough in Catheter-Interventional therapy for chronic thromboembolic pulmonary hypertension. JACC Cardiovasc Interv. 2014;7(11):1297-306. DOI:10.1016/j.jcin.2014.06.010.; Ogo T. Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. Current Opinion in Pulmonary Medicine. 2015;21(5):425-31. DOI:10.1097/MCP.0000000000000188.; Shimokawahara H, Nagayoshi S, Ogawa A, Matsubara H Continual Improvement in Pressure Gradient at the Lesion after Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. Can J Cardiol 2021;S0828-282X(21)00158-6. DOI:10.1016/j.cjca.2021.03.009.; Lang IM, Madani MM. Update on chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv. 2014;130(6):508-18. DOI:10.1161/CIRCULATIONAHA.114.009309.; Dimopoulos K, Kempny A, Alonso-Gonzalez R, et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension: challenges and future direction. Int J Cardiol. 2015;187:401-3. DOI:10.1016/j.ijcard.2015.03.361.; Sugimura K, Fukumoto Y, Satoh K, et al. Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J. 2012;(76):485-8. DOI:10.1253/circj.cj-11-1217.; Minatsuki S, Kiyosue A, Kodera S, et al. Effectiveness of balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension despite having lesion types suitable for surgical treatment. Journal of Cardiology. 2020;75(2):182-8. DOI:10.1016/j.jjcc.2019.07.006.; Mayer E, Jenkins D, Lindner J, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Car- diovasc Surg. 2011;(141):702-10. DOI:10.1016/j.jtcvs.2010.11.024.; Марукян Н.В., Симакова М.А., Моисеева О.М., и др. Способ баллонной ангиопластики ветвей легочной артерии у пациентов с хронической тромбоэмболической легочной гипертензией. Патент № 2716455, выдан 11.03.2020, заявка № 2019125445 от 27.05.2019.; https://www.rpcardio.com/jour/article/view/2438

Availability: https://www.rpcardio.com/jour/article/view/2438
https://doi.org/10.20996/1819-6446-2021-04-02

Практические рекомендации по лекарственному лечению рака желудка

Authors: Н. С. Бесова, А. А. Трякин, Е. В. Артамонова, Л. В. Болотина, А. Е. Калинин, П. В. Кононец, В. К. Лядов, О. В. Малихова, С. Н. Неред, С. А. Проценко, А. Б. Рябов, И. С. Стилиди, М. Д. Тер-Ованесов, В. М. Хомяков

Source: Malignant tumours; Том 10, № 3s2-1 (2020); 334-349 ; Злокачественные опухоли; Том 10, № 3s2-1 (2020); 334-349 ; 2587-6813 ; 2224-5057

Subject Terms: HER2, аденокарцинома желудка, аденокарцинома пищеводножелудочного перехода, лекарственная терапия, химиотерапия, трастузумаб, рамуцирумаб, ЭГДС, FISH

File Description: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/769/534; https://www.malignanttumors.org/jour/article/view/769

Availability: https://www.malignanttumors.org/jour/article/view/769
https://doi.org/10.18027/2224-5057-2020-10-3s2-21

Real world practice of medical treatment for moderate and severe inflammatory bowel diseases in Russian Federation, Republic of Belarus and Republic of Kazakhstan: intermediate results of the INTENT study ; Реальная практика лекарственной терапии среднетяжелых и тяжелых форм воспалительных заболеваний кишечника в России, Республике Беларусь и Республике Казахстан. Промежуточные результаты исследования INTENT

Authors: Knyazev O.V., Belousova E.A., Abdulganieva D.I., Gubonina I.V., Kaibullayeva J.A., Marakhouski Y.K., Chashkova E.Y., Shapina M.V., Shchukina O.B., Gegenava B.B., Oliferuk N.S.

Source: Almanac of Clinical Medicine; Vol 49, No 7 (2021); 443-454 ; Альманах клинической медицины; Vol 49, No 7 (2021); 443-454 ; 2587-9294 ; 2072-0505

Subject Terms: inflammatory bowel diseases, Crohn's disease, ulcerative colitis, epidemiology, medical treatment, real world clinical practice, 5-aminosalicylic acid, glucocorticosteroids, immunosuppressants, genetically engineered biological agents, vedolizumab, воспалительные заболевания кишечника, болезнь Крона, язвенный колит, эпидемиология, лекарственная терапия, реальная клиническая практика, 5-аминосалициловая кислота, глюкокортикостероиды, иммуносупрессоры, генно-инженерные биологические препараты, ведолизумаб

File Description: application/pdf

Relation: https://almclinmed.ru/jour/article/view/1619/1399; https://almclinmed.ru/jour/article/downloadSuppFile/1619/2666; https://almclinmed.ru/jour/article/downloadSuppFile/1619/2667; https://almclinmed.ru/jour/article/downloadSuppFile/1619/2668; https://almclinmed.ru/jour/article/downloadSuppFile/1619/2669; https://almclinmed.ru/jour/article/downloadSuppFile/1619/2670; https://almclinmed.ru/jour/article/downloadSuppFile/1619/2671; https://almclinmed.ru/jour/article/downloadSuppFile/1619/2672; https://almclinmed.ru/jour/article/view/1619

Availability: https://almclinmed.ru/jour/article/view/1619
https://doi.org/10.18786/2072-0505-2021-49-061